gc syndrome - Health Topics
The Victoria Advocate: GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval
May 28, 2026
The Victoria Advocate: GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval FOX8 Cleveland: European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma's Treatment for Sanfilippo Syndrome (Type A) European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma's Treatment for Sanfilippo Syndrome (Type A) Fox 5 San Diego: GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval